Trial Profile
Mesylate apatinib as monotherapy or in combination with capecitabine in the treatment of advanced breast cancer multicenter, open, single arm clinical study
Status:
Not yet recruiting
Phase of Trial:
Phase IV
Latest Information Update: 17 Jan 2018
Price :
$35
*
At a glance
- Drugs Rivoceranib (Primary) ; Capecitabine
- Indications Advanced breast cancer
- Focus Adverse reactions; Therapeutic Use
- 17 Jan 2018 New trial record